AOD 9604 Dosage & Side Effects Guide

AOD 9604 dosing in research contexts follows body weight tiers. These doses come from community protocols and the original clinical trial data, not from FDA-approved prescribing guidelines (none exist).

Timing matters. AOD 9604 is administered on an empty stomach, typically first thing in the morning or before bed. Food intake (particularly carbohydrates) within 30 minutes of injection may reduce effectiveness by altering the metabolic state the peptide targets.

Cycle length. Research protocols typically run 12 weeks, matching the original Phase 2b trial duration. Some protocols extend to 16 weeks. There is no established data on long-term use.

Reconstitution. AOD 9604 is supplied as lyophilized powder. Standard reconstitution uses bacteriostatic water. A 5 mg vial reconstituted with 1 mL of bacteriostatic water produces a 5 mg/mL concentration. Use our reconstitution calculator for exact measurements.

For general injection guidance, see our how to inject peptides guide.

AOD 9604 targets fat metabolism through two pathways.

Lipolysis stimulation. The peptide activates beta-3 adrenergic receptors on fat cells, triggering the release of stored fatty acids into the bloodstream for energy use. This is the same pathway that exercise and fasting activate, but AOD 9604 does it without the catecholamine release (no heart rate increase or jitteriness).

Lipogenesis inhibition. AOD 9604 reduces the rate at which the body converts excess calories into stored fat. In animal studies, this dual mechanism produced measurable fat reduction in obese mice.

The critical distinction from full HGH: AOD 9604 does not activate the IGF-1 pathway. Full growth hormone increases IGF-1 levels, which drives muscle growth but also raises blood sugar and carries cancer risk with long-term use. AOD 9604 isolates the fat-burning fragment without these systemic effects.

This mechanism was confirmed in preclinical models. The failure occurred in translating these results to humans at the doses tested in the Phase 2b trial.

The pivotal AOD 9604 clinical trial (Metabolic Pharmaceuticals, 2007) enrolled 536 obese patients across multiple sites in Australia. Patients received daily oral AOD 9604 at doses of 1 mg, 5 mg, or 10 mg, or placebo, for 12 weeks.

The trial failed its primary endpoint. None of the AOD 9604 groups showed statistically significant weight loss compared to placebo. Metabolic Pharmaceuticals' stock crashed, and the company abandoned further development.

Important context: The trial used oral dosing, not injection. Peptide bioavailability through oral administration is notoriously low (often below 1%). Some researchers argue that injectable AOD 9604 could produce different results, but this has never been tested in a controlled human trial.

The company did report that AOD 9604 showed a favorable safety profile with no significant adverse effects compared to placebo. The peptide is not dangerous. It just did not demonstrate efficacy in this trial design.

AOD 9604 has one of the milder side effect profiles among research peptides. The Phase 2b trial showed no significant difference in adverse events between AOD 9604 and placebo groups.

What AOD 9604 does NOT cause (based on available data):

• No blood sugar changes. Unlike full HGH, AOD 9604 does not affect glucose metabolism.
• No IGF-1 elevation. No growth-related side effects (joint pain, carpal tunnel, organ enlargement) associated with HGH use.
• No water retention. Unlike full HGH, which causes significant water retention in many users.
• No cortisol changes. No reported effects on the HPA axis.

The safety profile is the strongest argument for AOD 9604 in research contexts. It carries minimal risk compared to full growth hormone or other fat-loss peptides. The weakness is on the efficacy side, not the safety side.

For comparison with other fat-loss peptides, see our tesamorelin dosage guide and sermorelin for fat loss.

AOD 9604 occupies a complicated regulatory space.

FDA 503A exclusion (2024). The FDA added AOD 9604 to the list of substances that cannot be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act. This means licensed compounding pharmacies cannot legally prepare AOD 9604 for individual patients in the United States. The FDA cited insufficient safety and efficacy data.

WADA banned. The World Anti-Doping Agency prohibits AOD 9604 in competition under the category of "Peptide Hormones, Growth Factors, Related Substances and Mimetics." Athletes testing positive face sanctions.

Research chemical status. AOD 9604 remains available from research chemical suppliers as a "research use only" compound. This is the gray area where most users acquire it. Research chemicals are not regulated as drugs but are technically not legal for human self-administration.

Australian TGA. In Australia, where AOD 9604 was originally developed, it has been available as an over-the-counter supplement in some formulations, though this status has been debated.

For the broader regulatory landscape affecting peptides, see our FDA peptide crackdown analysis and where to buy peptides in 2026.

AOD 9604 is the cheapest option with the weakest evidence. Semaglutide and tirzepatide are the most expensive with the strongest evidence (FDA-approved, large RCTs showing 15-22% weight loss).

For patients seeking pharmaceutical fat loss with proven efficacy, GLP-1 drugs are the clear choice. For researchers interested in a low-side-effect peptide with theoretical fat-loss mechanisms, AOD 9604 remains in the conversation despite its clinical failure.

See our semaglutide dosage chart and tirzepatide dosage chart for FDA-approved weight loss medication dosing.